Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Average Recommendation of “Buy” from Brokerages

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned a consensus rating of “Buy” from the eleven brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $66.00.

MAZE has been the subject of a number of research analyst reports. Wedbush raised their target price on Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Guggenheim raised their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. HC Wainwright raised their target price on Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. JPMorgan Chase & Co. raised their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, March 31st. Finally, Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th.

Maze Therapeutics Trading Up 2.2%

MAZE opened at $25.40 on Friday. The stock has a market cap of $1.41 billion, a PE ratio of -10.04 and a beta of 2.26. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The business has a 50 day moving average of $26.86 and a 200-day moving average of $37.36. Maze Therapeutics has a 52 week low of $9.83 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million during the quarter. Equities research analysts predict that Maze Therapeutics will post -2.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at approximately $266,461.11. The trade was a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the transaction, the senior vice president owned 12,965 shares of the company’s stock, valued at $381,689.60. The trade was a 16.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 119,502 shares of company stock worth $4,246,639 over the last three months. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MAZE. Janus Henderson Group PLC raised its stake in Maze Therapeutics by 318.0% during the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. raised its stake in Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after buying an additional 915,342 shares during the last quarter. Marshall Wace LLP raised its stake in Maze Therapeutics by 3,868.5% during the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after buying an additional 758,104 shares during the last quarter. Caligan Partners LP purchased a new position in Maze Therapeutics during the fourth quarter valued at $22,794,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in Maze Therapeutics during the third quarter valued at $14,135,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.